Most profitable less than $5 stock in the world?
This virtually unknown stock trades under a secret name, brings in more cash than IBM, Facebook and Tesla, and trades for just under $5.

Find out why in this "leaked" footage from a former Wall Street money manager.
Pardeep Nijhawan, insider at Edesa Biotech

Pardeep Nijhawan Insider Information

Founder of Exzell Pharma, Medical Futures, Inc., Edesa Biotech, Inc. (Old) and Digestive Health Clinic LLC, Pardeep Nijhawan presently occupies the position of Chief Executive Officer, Secretary & Director at Edesa Biotech, Inc.

He previously occupied the position of Chief Executive Officer & Director at Edesa Biotech, Inc. (Old) and Chief Executive Officer for Medical Futures, Inc.

He received a doctorate from the University of Ottawa.

What is Pardeep Nijhawan's net worth?

The estimated net worth of Pardeep Nijhawan is at least $1.17 million as of June 30th, 2022. Dr. Nijhawan owns 594,812 shares of Edesa Biotech stock worth more than $1,165,832 as of August 15th. This net worth estimate does not reflect any other investments that Dr. Nijhawan may own. Additionally, Dr. Nijhawan receives an annual salary of $498,770.00 as CEO at Edesa Biotech. Learn More about Pardeep Nijhawan's net worth.

How old is Pardeep Nijhawan?

Dr. Nijhawan is currently 51 years old. There are 2 older executives and no younger executives at Edesa Biotech. Learn More on Pardeep Nijhawan's age.

What is Pardeep Nijhawan's salary?

As the CEO of Edesa Biotech, Inc., Dr. Nijhawan earns $498,770.00 per year. Learn More on Pardeep Nijhawan's salary.

How do I contact Pardeep Nijhawan?

The corporate mailing address for Dr. Nijhawan and other Edesa Biotech executives is 100 SPY COURT, MARKHAM A6, L3R 5H6. Edesa Biotech can also be reached via phone at (289) 800-9600 and via email at [email protected] Learn More on Pardeep Nijhawan's contact information.

Has Pardeep Nijhawan been buying or selling shares of Edesa Biotech?

Pardeep Nijhawan has not been actively trading shares of Edesa Biotech in the last ninety days. Most recently, on Thursday, June 30th, Pardeep Nijhawan bought 20,000 shares of Edesa Biotech stock. The stock was acquired at an average cost of $1.60 per share, with a total value of $32,000.00. Following the completion of the transaction, the chief executive officer now directly owns 594,812 shares of the company's stock, valued at $951,699.20. Learn More on Pardeep Nijhawan's trading history.

Who are Edesa Biotech's active insiders?

Edesa Biotech's insider roster includes Michael Brooks (President), and Pardeep Nijhawan (CEO). Learn More on Edesa Biotech's active insiders.

Are insiders buying or selling shares of Edesa Biotech?

In the last year, Edesa Biotech insiders bought shares 15 times. They purchased a total of 56,500 shares worth more than $121,267.50. The most recent insider tranaction occured on June, 30th when CEO Pardeep Nijhawan bought 20,000 shares worth more than $32,000.00. Insiders at Edesa Biotech own 29.5 % of the company. Learn More about insider trades at Edesa Biotech.

Information on this page was last updated on 6/30/2022.

Pardeep Nijhawan Insider Trading History at Edesa Biotech

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/30/2022Buy20,000$1.60$32,000.00594,812View SEC Filing Icon  
5/27/2022Buy5,000$1.92$9,600.00574,812View SEC Filing Icon  
5/24/2022Buy2,000$1.80$3,600.00569,812View SEC Filing Icon  
3/31/2022Buy2,000$2.99$5,980.00View SEC Filing Icon  
3/29/2022Buy2,000$3.02$6,040.00View SEC Filing Icon  
3/17/2022Buy2,000$3.26$6,520.00View SEC Filing Icon  
3/15/2022Buy2,000$2.80$5,600.00View SEC Filing Icon  
3/11/2022Buy7,000$3.09$21,630.00View SEC Filing Icon  
3/9/2022Buy1,500$3.05$4,575.00View SEC Filing Icon  
3/29/2021Buy2,000$5.23$10,460.00547,312View SEC Filing Icon  
3/24/2021Buy5,000$5.16$25,800.00542,312View SEC Filing Icon  
5/26/2020Buy3,000$3.18$9,540.00537,312View SEC Filing Icon  
3/17/2020Buy5,000$1.87$9,350.00537,312View SEC Filing Icon  
See Full Table

Pardeep Nijhawan Buying and Selling Activity at Edesa Biotech

This chart shows Pardeep Nijhawan's buying and selling at Edesa Biotech by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Edesa Biotech Company Overview

Edesa Biotech logo
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Read More

Today's Range

Now: $1.96
Low: $1.96
High: $2.08

50 Day Range

MA: $1.77
Low: $1.47
High: $2.33

2 Week Range

Now: $1.96
Low: $1.30
High: $12.00


37,112 shs

Average Volume

76,221 shs

Market Capitalization

$30.31 million

P/E Ratio


Dividend Yield



A One Stop Shop for Everything Futures Trading
Whether you're looking to learn the basics of futures or are a seasoned vet looking to hone your trading skills, our Technical Analysis Guide has everything you need to succeed in today's futures markets!
Download your FREE Technical Analysis Trading Guide Today.